Меланома нижнего женского полового тракта (вульвы, влагалища и шейки матки): обзор литературы и собственные наблюдения

В статье освещены особенности диагностики, клиническая картина и различные подходы к лечению меланом вульвы, влагалища и шейки матки.

1. Tacastacas J.D., Bray J., Cohen Y.K. et al. Update on primary mucosal melanoma. J Am Acad Dermatol 2014;71 (2):366—75.

2. Creasman W.T., Phillips J.L., Menck H.R. A survey of hospital management practices for vulvar melanoma. J Am Coll Surg 1999;188:670-5.

3. Stang A., Streller B., Eisinger B. et al. Population-based incidence rates of malignant melanoma of the vulva in Germany. Gynecol Oncol 2005;96:216-21.

4. Chang A.E., Karnell L.H., Menck H.R. The National Cancer Data Base report on cutaneous and noncutaneous melanoma: a summary of 84,836 cases from the past decade. The American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer 1998;83:1664-78.

5. Vyas R., Thompson C., Zargar H. et al. Epidemiology of genitourinary melanoma in the United States: 1992 through 2012. J Am Acad Dermatol 2016;75 (1):144—50.

6. Hu D.N., Yu G.P., McCormick S.A. Population-based incidence of vulvar and vaginal melanoma in various races and ethnic groups with comparisons to other site-specific melanomas. Melanoma Res 2010;20:153-8.

7. Stang A., Streller B., Eisinger B. et al. Population-based incidence rates of malignant melanoma of the vulva in Germany. Gynecol Oncol 2005;96:216-21.

8. Sugiyama V.E., Chan J.K., Shin J.Y. et al. Vulvar melanoma: a multivariable analysis of 644 patients. Obstet Gynecol 2007:110:296-301.

9. Aulmann S., Sinn H.P., Penzel R. et al. Comparison of molecular abnormalities in vulvar and vaginal melanomas. Mod Pathol 2014:27:1386-93.

10. Ragnarsson-Olding B., Johansson H., Rutqvist L.E. et al. Malignant melanoma of the vulva and vagina. Trends in incidence, age distribution, and long-term survival among 245 consecutive cases in Sweden 1960-1984. Cancer 1993;71:1893-7.

11. Gökaslan H., Sişmanoğlu A., Pekin T. et al. Primary malignant melanoma of the vagina: a case report and review of the current treatment options. Eur J Obstet Gynecol Reprod Biol 2005;121:243-8.

12. Kalampokas E., Kalampokas T., Damaskos C. Primary vaginal melanoma, a rare and aggressive entity. A case report and review of the literature. In Vivo 2017:31:133-9.

13. Frumovitz M., Etchepareborda M., Sun C.C. et al. Primary malignant melanoma of the vagina. Obstet Gynecol 2010;116:1358-65.

14. Pusceddu S., Bajetta E., Carcangiu M.L. et al. A literature overview of primary cervical malignant melanoma: an exceedingly rare cancer. Crit Rev Oncol Hematol 2012;81:185-95.

15. Bishop K.D., Olszewski A.J. Epidemiology and survival outcomes of ocular and mucosal melanomas: a population-based analysis. Int J Cancer 2014;134:2961-71.

16. Pleunis N., Schuurman M.S., Van Rossum M.M. et al. Rare vulvar malignancies; incidence, treatment and survival in the Netherlands. Gynecol Oncol 2016;142:440-5.

17. Verschraegen C.F., Benjapibal M., Supakarapongkul W. et al. Vulvar melanoma at the M.D. Anderson Cancer center: 25 years later. Int J Gynecol Cancer 2011;11:359-64.

18. Seifried S., Haydu L.E., Quinn M.J. et al. Melanoma of the vulva and vagina: principles of staging and their relevance to management based on a clinicopatho-logic analysis of 85 cases. Ann Surg Oncol 2015;22:1959-66.

19. Look K. Y., Roth L.M., Sutton G.P. Vulvar melanoma reconsidered. Cancer 1993;72:143-6.

20. Trimble E. L., Lewis J.L., Williams L.L. et al. Management of vulvar melanoma. Gynecol Oncol 1992;45:254-25.

21. Kirschner A.N., Kidd E.A., Dewees T., Perkins S.M. Treatment approach and outcomes of vaginal melanoma. Cancer 2013;23:1484-9.

22. Huang Q., Huang H., Wan T. et al. Clinical outcome of 31 patients with primary malignant melanoma of the vagina. J Gynecol Oncol 2013;24:330-5.

23. Buchanan D.J., Schlaerth J., Kurosaki T. Primary vaginal melanoma: thirteenyear disease-free survival after wide local excision and review of recent literature. Am J Obstet Gynecol 1998;178:1177-84.

24. Clark K.C., Butz W.R., Hapke M.R. Primary malignant melanoma of the uterine cervix: case report with world literature review. Int J Gynecol Pathol 1999;18:265-73.

25. Cantuaria G., Angioli R., Fernandez-Abril A., Penalver M. Primary malignant melanoma of the uterine cervix: case report and review of the literature. Prim Care Update Ob Gyns 1998;5:159-60.

26. Rohwedder A., Philips B., Malfetano J. et al. Vulvar malignant melanoma associated with human papillomavirus DNA: report of two cases and review of literature. Am J Dermatopathol 2002;24:230-40.

27. Omholt K., Grafstrom E., Kanter Lewensohn L. KIT pathway alterations in mucosal melanomas of the vulva and other sites. Clin Cancer Res 2001;17:3933-42.

28. Aulmann S., Sinn H.P., Penzel R. et al. Comparison of molecular abnormalities in vulvar and vaginal melanomas. Mod Pathol 2014;27:1386-93.

29. Mordel N., Mor-Yosef S., Ben-Baruch N., Anteby S.O. Malignant melanoma of the uterine cervix: case report and review of the literature. Gynecol Oncol 1989;32:375-80.

30. An J., Li B., Wu L. et al. Primary malignant amelanotic melanoma of the female genital tract: report of two cases and review of literature. Melanoma Res 2009;19:267-70.

31. Noguchi T., Ota N., Mabuchi Y. et al. A case of malignant melanoma of the uterine cervix with disseminated metastases throughout the vaginal wall. Case Rep Obstet Gynecol 2017: (2017):5656340.

32. Norris H.J., Taylor H.B. Melanomas of the vagina. Am J Clin Pathol 1966;46:420-6.

33. Gleason B.G., Hirsch M.N., Nucci M.R. et al. Atypical genital nevi. A clinicopathologic analysis of 56 cases. Am J Surg Pathol 2008;32:51-7.

34. Hou J.Y., Baptiste C., Hombalegowda R.B. et al. Vulvar and vaginal melanoma: a unique subclass of mucosal melanoma based on a comprehensive molecular analysis of 51 cases compared with 2253 cases of nongynecologic melanoma. Cancer 2017;123:1333-44.

35. Sugiyama V.E., Chan J.K., Kapp D.S. Management of melanomas of the female genital tract. Curr Opin Oncol 2008;20:565-9.

36. Leitao Jr.M.M. Management of vulvar and vaginal melanomas: current and future strategies. Am Soc Clin Oncol Educ Book 2014:e277-81.

37. Karasawa K., Wakatsuki M., Kato S. et al. Working Group for Gynecological Tumors. Clinical trial of carbon ion radiotherapy for gynecological melanoma. J Radiat Res 2014;55:343-50.

38. Leitao Jr.M.M., Cheng X., Hamilton A.L. et al. Gynecologic Cancer Inter Group (GCIG) consensus review for vulvovaginal melanomas. Int J Gynecol Cancer 2014;24 (9 Suppl 3):S117—22.

39. Janco J.M., Markovic S.N., Weaver A.L. et al. Vulvar and vaginal melanoma: case series and review of current management options including neoadjuvant chemotherapy. Gynecol Oncol 2013;129:533-7.

40. Sinasac S.E., Petrella T.M., Rouzbah-man M. et al. Melanoma of the vulva and vagina: surgical management and outcomes based on a clinicopathologic review of 68 cases. J Obstet Gynaecol Can 2019;41(6):762-71.

41. Gadducci A., Carinelli S., Guerri-eri M.E., Aletti G.D. Melanoma of the lower genital tract: Prognostic factors and treatment modalities. Gynecol Oncol 2018;150(1):180-9.

42. Danish H.H., Patel K.R., Switchenko J.M. et al. The influence of postoperative lymph node radiation therapy on overall survival of patients with stage III melanoma, a National Cancer Database analysis. Melanoma Res 2016;26:595-603.

43. Slingluff C.L., Flaherty K., Posenberg S. A. et al. Cutaneous melanoma. In: Cancer: Principles and practice of oncology. 9th edn. Eds.: V. T. DeVita, T. S. Lawrence, S.A. Rosenberg. Philadelphia: Lippincott Williams & Wilkins, 2011. Pp. 1643-1691.

44. Piura B. Management of primary melanoma of the female urogenital tract. Lancet Oncol 2008;9:973-81.

45. Wilson M.A., Schuchter L.M. Chemotherapy for melanoma. Cancer Treat Res 2016;167:209-29.

46. Harting M.S., Kim K.B. Biochemotherapy in patients with advanced vulvovaginal mucosal melanoma. Melanoma Res 2004; 14:517-20.

47. Volpe V.O., Klufas D.M., Hegde U. The new paradigm of systemic therapies for metastatic melanoma. J Am Acad Dermatol 2017;77:356-68.

48. Chapman P.B., Hauschild A., Robert C. et al. BRIM-3 Study Group, Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011;364:2507-16.